Phosphorus Metabolism Disorders: Clinical Trials

43 trials for Phosphorus Metabolism Disorders, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

32 completed, 5 recruiting, 5 unknown, 1 terminated. 43 Phase 2, 8 Phase 1, 2 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 243Completed 32, Recruiting 5, Unknown 5, Terminated 1
Phase 18Completed 5, Unknown 2, Recruiting 1
Phase 32Completed 2

Follow Phosphorus Metabolism Disorders: new trials by email Literature Review of Phosphorus Metabolism Disorders trials Research Report on Phosphorus Metabolism Disorders

Trials (filtered) newest first · largest first

All 43 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Phosphate in Acute Pancreatitis
Sodium Phosphate, Potassium Phosphate - Pancreatitis
Phase 2RecruitingDuke University1002026-07-092026-08-26
A Study to Evaluate Safety, Tolerability and Efficacy of AP306 at Fixed Doses in Dialysis Participants With Hyperphosphatemia
AP306 75 mg BID, AP306 125 mg BID, AP306 150 mg BID - Hyperphosphatemia, Chronic Kidney Disease Requiring Chronic Dialysis
Phase 2RecruitingR1 Therapeutics1682026-06-012026-08-26
Evaluation of Dipyridamole in Preventing Post-Transplant Hypophosphatemia in Kidney Transplant Recipients
Dipyridamole 75 MG - Hypophosphatemia, Kidney Transplantation
Phase 2RecruitingStanford University902025-05-152026-06-11
Evaluate the Efficacy and Safety of JMKX003002 in End-Stage Renal Disease Patients on Hemodialysis with Hyperphosphatemia
JMKX003002 will be administered orally, Sevelamer carbonate - Hyperphosphatemia
Phase 2RecruitingJemincare502024-12-302025-02-03
A First-in-human Study of KK8123 in Adults With X-linked Hypophosphatemia
KK8123 - X-linked Hypophosphatemia
Phase 1 / Phase 2RecruitingKyowa Kirin Co., Ltd.392024-10-092026-11-06
A Study to Evaluate Safety and Efficacy of AP-306 in Hyperphosphatemia Patients
AP-306, Sevelamer Carbonate - Chronic Kidney Diseases, Hyperphosphatemia
Phase 2CompletedAlebund Pharmaceuticals552023-02-202024-01-10
To Evaluate the Patient Tolerance, Pharmacodynamics and Pharmacokinetics of Lanthanum Polystyrene Sulfonate Powder
Lanthanum Polystyrene Sulphonate Powder, Lanthanum Carbonate 500 MG, Placebo - Hyperphosphatemia
Phase 1 / Phase 2UnknownGrand Life Science (Liaoning) Co., Ltd.482020-10-212021-07-28
A Phase 2 Study to Evaluate the Safety and Efficacy of VS-505(AP301) to Treat Hyperphosphatemia in Hemodialysis Patients
VS-505, Sevelamer Carbonate - Hyperphosphatemia
Phase 2CompletedShanghai Alebund Pharmaceuticals Limited1582020-10-132022-10-18
Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Burosumab in Patients Less Than 1 Year of Age
Burosumab - X-linked Hypophosphatemia (XLH)
Phase 1 / Phase 2CompletedKyowa Kirin Pharmaceutical Development Ltd162020-02-262024-11-07
Phosphate Binder-combination Study of KHK7791 in Hyperphosphatemia Patients
KHK7791, Placebp - Hyperphosphatemia
Phase 2CompletedKyowa Kirin Co., Ltd.472019-04-292024-03-07
Dose-finding Study of KHK7791 in Hyperphosphatemia Patients
KHK7791, Placebo - Hyperphosphatemia
Phase 2CompletedKyowa Kirin Co., Ltd.2072019-04-152024-03-07
Study to Evaluate the Efficacy of Tenapanor as Adjunctive Therapy to Phosphate Binder Therapy
Tenapanor, Placebo, Phosphate Binder Agents - Hyperphosphatemia
Phase 2 / Phase 3CompletedArdelyx2362019-02-282023-03-06
BGJ398 for the Treatment of Tumor-Induced Osteomalacia
BGJ398 - Tumor-Induced Osteomalacia, Oncogenic Osteomalacia
Phase 2TerminatedNational Institute of Dental and Craniofacial Research (NIDCR)42019-02-272026-11-10
A Phosphate Binder Switch Study of KHK7791 in Hyperphosphatemia Patients on HD
KHK7791 - Hyperphosphatemia
Phase 2CompletedKyowa Kirin Co., Ltd.672018-12-272024-03-07
Study of the Safety, Pharmacodynamics (PD) and Efficacy of KRN23 in Children From 1 to 4 Years Old With X-linked Hypophosphatemia (XLH)
Burosumab - X-Linked Hypophosphatemia
Phase 2CompletedKyowa Kirin, Inc.132016-05-052024-05-06
A Dose Escalation Study of VS-505 in End Stage Renal Disease Patients Undergoing Hemodialysis
VS-505 - End Stage Renal Disease, Hyperphosphatemia
Phase 1 / Phase 2UnknownKDL Inc.302015-06-012016-02-08
Long-Term Extension Study of KRN23 in Adult Subjects With X-Linked Hypophosphatemia (XLH)
KRN23 - X-Linked Hypophosphatemia
Phase 2CompletedKyowa Kirin, Inc.202015-01-302024-05-06
Study of KRN23 (Burosumab), a Recombinant Fully Human Monoclonal Antibody Against Fibroblast Growth Factor 23 (FGF23), in Pediatric Subjects With X-linked Hypophosphatemia (XLH)
burosumab - X-linked Hypophosphatemia
Phase 2CompletedKyowa Kirin, Inc.522014-07-022024-05-06
Study to Evaluate the Efficacy and Safety of PT20 in Subjects With Hyperphosphataemia and Dialysis Dependent Chronic Kidney Disease
PT20, Placebo - Hyperphosphataemia
Phase 2CompletedPhosphate Therapeutics1532014-05-072018-01-16
Dose Finding Study to Treat High Phosphate Levels in the Blood.
AZD1722, Placebo - Hyperphosphatemia
Phase 2CompletedArdelyx1622014-03-012020-09-14

Showing 20 of 43. Sign in to see all of them.

Narrower conditions

Hyperphosphatemia (32)  ·  Renal Insufficiency, Chronic (11)  ·  Familial Hypophosphatemic Rickets (8)  ·  Kidney Failure, Chronic (8)  ·  Hypophosphatemia (5)  ·  Kidney Diseases (4)  ·  Renal Insufficiency (2)  ·  Bone Diseases (1)  ·  Bone Diseases, Metabolic (1)  ·  Bronchiolitis Obliterans Syndrome (1)  ·  Chronic Kidney Disease-Mineral and Bone Disorder (1)  ·  Inflammation (1)  ·  Metabolic Diseases (1)  ·  Musculoskeletal Diseases (1)  ·  Oncogenic osteomalacia (1)

Broader conditions

Nutritional and Metabolic Diseases (43)  ·  Metabolic Diseases (42)  ·  Female Urogenital Diseases and Pregnancy Complications (28)  ·  Urogenital Diseases (28)  ·  Female Urogenital Diseases (27)  ·  Male Urogenital Diseases (27)  ·  Urologic Diseases (27)  ·  Kidney Diseases (23)  ·  Disease Attributes (19)  ·  Pathologic Processes (19)  ·  Pathological Conditions, Signs and Symptoms (19)  ·  Chronic Disease (18)  ·  Renal Insufficiency (16)  ·  Avitaminosis (9)

Interventions

Sevelamer (10)  ·  burosumab (6)  ·  lanthanum carbonate (4)  ·  tenapanor (3)  ·  Calcium Carbonate (2)  ·  Niacinamide (2)  ·  SBR 759 (2)  ·  ferric citrate (2)  ·  iron-magnesium hydroxycarbonate (2)  ·  potassium phosphate (2)  ·  BID protein, human (1)  ·  Dipyridamole (1)  ·  Geritol (1)  ·  Growth Hormone (1)  ·  Iron (1)

Sponsors

Kyowa Kirin Co., Ltd. (6)  ·  Kyowa Kirin, Inc. (3)  ·  Ardelyx (2)  ·  Bayer (2)  ·  Genzyme, a Sanofi Company (2)  ·  Ineos Healthcare Limited (2)  ·  KDL Inc. (2)  ·  Novartis Pharmaceuticals (2)  ·  Alebund Pharmaceuticals (1)  ·  Astellas Pharma Inc (1)  ·  Bicetre Hospital (1)  ·  Duke University (1)  ·  Fresenius Medical Care Deutschland GmbH (1)  ·  Grand Life Science (Liaoning) Co., Ltd. (1)  ·  Ilypsa (1)

Countries

United States (21)  ·  Japan (9)  ·  United Kingdom (7)  ·  Germany (6)  ·  China (5)  ·  France (5)  ·  Canada (4)  ·  Poland (3)  ·  Australia (2)  ·  Italy (2)  ·  Puerto Rico (2)  ·  Spain (2)  ·  Sweden (2)  ·  Argentina (1)  ·  Austria (1)

Top investigators

Amy Zhang, PhD (2)  ·  Alan H Lau, Pharm.D. (1)  ·  Alex Mullen (1)  ·  Daniel O Young, MD (1)  ·  David P Rosenbaum, PhD (1)  ·  Geoff Block, MD (1)  ·  Geoffrey A Block, MD (1)  ·  Guido Smeets, MD (1)  ·  Johan Rosman, MD, Ph.D (1)  ·  Julia B Lewis, MD (1)

Results publications

PMID 40576086, PMID 21854503, PMID 25919461, PMID 32721016, PMID 38323855, PMID 39151033, PMID 19776051, PMID 21426511, PMID 24968790, PMID 24975892, PMID 26073451, PMID 28822957, PMID 29617976, PMID 29791829, PMID 30638856, PMID 32651955, PMID 33766811, PMID 34636899, PMID 35236302, PMID 36072994, PMID 38453435, PMID 42044650

NIH funding

2009 (1), R01DK142980 (1)